Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The present study evaluated the role of various neurotransmitter systems in mediating buspirone's blockade of the fear-potentiated startle effect, where acoustic startle amplitude is normally increase in the presence of a light previously paired with a shock. Large lesions of the dorsal and median raphe nuclei or IP injections of the serotonin antagonists cinanserin (10 mg/kg) or cyproheptadine (5 mg/kg) did not alter fear-potentiated startle, nor did these treatments prevent buspirone (5 or 10 mg/kg SC) from blocking fear-potentiated startle. The 5-HT 1A agonist 8-OH-DPAT (2.5-10.0) did not block fear-potentiated startle even at doses that produced a marked "5-HT syndrome". Another 5-HT 1A agonist, ipsapirone (10-20 mg/kg), blocked potentiated startle only at a very high dose (40 mg/kg). p-Chlorophenylalanine and p-chloroamphetamine did not alter fear-potentiated startle. Finally, pretreatment with the benzodiazepine receptor antagonist RO-15-1788 (1 mg/kg); the opiate antagonist naloxone (2 mg/kg) or the alpha 2-adrenergic antagonist yohimbine (5 mg/kg) did not reduce fear-potentiated startle, nor did they prevent buspirone from blocking fear-potentiated startle. Taken together, the data do not support the hypothesis that buspirone's anxiolytic effects are mediated by actions at 5-HT 1A receptors and more generally indicate that serotonergic neurons do not play an important role in fear-potentiated startle.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in line with the clinical observation that specific phobias respond less well to treatments such as citalopram than other pathological anxiety states (Baldwin et al, 2005) and with preclinical evidence in rodents showing that the serotonergic system may not be critical for the expression of phasic fear-potentiated startle (Davis et al, 1988).”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as Davis et al, 1988
Citations
Cites
Pazos, A., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855 · cited 1×
“Binding studies have indicated that the hippocampus has high densities of 5-HT1A binding sites (Pazos and Palacios 1985).”
BackgroundReconciling the role of central serotonin neurons in human and animal behavior
Soubrié, P. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00022871 · Cited by 996
Tricklebank, M. D., Forler, C., & Fozard, J. R. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90714-3 · Cited by 675 · cited 1×
“Moreover, exploratory studies showed that pindolol (10 mg/kg), another 5-HT1 antagonist (Tricklebank et al. 1984), also did not prevent buspirone's anxiolytic effect.”
BackgroundAn animal behavior model for studying central serotonergic synapses
Jacobs, B. L. (1976) · Life Sciences · doi:10.1016/0024-3205(76)90303-9 · Cited by 556 · cited 2×
“1986) or only weakly effective (Hjorth and Carlsson 1982) at producing the °'5-HT syndrome" characteristic of 5-HT1A receptor activation (Jacobs 1976).”
BackgroundAfferent projections to the rat locus coeruleus as determined by a retrograde tracing technique
Cedarbaum, J. M., & Aghajanian, G. K. (1978) · Journal of Comparative Neurology · doi:10.1002/cne.901780102 · Cited by 549 · cited 1×
“Second, unlike clonidine, which depresses single unit firing of locus coeruleus neurons (Cedarbaum and Aghajanian 1978), buspirone actually increases locus coeruleus firing through a mechanism independent of ~2-adrenergic receptors (Sanghera and German 1983).”
BackgroundHitchcock, J., & Davis, M. (1986) · Behavioral Neuroscience · doi:10.1037/0735-7044.100.1.11 · Cited by 541
Self-citationThe neurobiology of the nucleus accumbens
Bailey, P. E. (1982) · Neuroscience · doi:10.1016/0306-4522(82)90145-2 · Cited by 451 · cited 1×
“As indicated in the Introduction, buspirone has been reported to bind to dopamine receptors (Stanton et al. 1981; Peroutka 1985).”
Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors
Peroutka, S. J. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90194-5 · Cited by 369 · cited 1×
“Buspirone produces an agonistlike reduction in serotonin turnover in various areas of the rodent brain (Hjorth and Carlsson 1982) and it binds with high affinity to 5-HT1 receptors (Glasser and Traber 1983), probably of the 5-HTIA subtype (Peroutka 1985).”
BackgroundPsychopharmacology: The Third Generation of Progress
ROGERS, K. L. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.9.1161 · Cited by 290
Pharmacology and neurochemistry of buspirone.
Riblet, L. A., Taylor, D. P., Eison, M. S., & Stanton, H. C. (1982) · PubMed · Cited by 287
Research works printed but not linked: 4
- Andrade R, Nicoll RA (1985) The novel anxiolytic buspirone elicits a small hyperpolarization and seduces serotonin responses at putative 5-HT1 receptors on hippocampal CA1 pyramidal cells. Soc Neurosci Abstr 11:597
- Lucki I, Ward HR (1986) Antagonism of serotonin-mediated behaviors in rats by pretreatment with the non-benzodiazepine anxiolytics buspirone or ipsapirone. Soc Neurosci Abstr 12:1236
- Mauk MD, Peroutka SJ, Kocsis JD (1985) Modulation of synaptic transmission in the hippocampus produced by novel anxiolytics (Buspirone, TVX-Q & DPAT). Soc Neurosci Abstr 11:135
- Reynolds LS, Seymour PA, Heym J (1986) Inhibition of the behavioral effects of 8-OH-DPAT by the novel anxiolytics buspirone, gepirone and isapirone. Soc Neurosci Abstr 12:481
Cited by
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
Self-citationFear-potentiated startle: A neural and pharmacological analysis
Davis, M., Falls, W. A., Campeau, S., & Kim, M. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90102-v · Cited by 748
Self-citationGriebel, G. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)98597-j · Cited by 488
DAVIS, M., WALKER, D. L., & LEE, Y. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48289.x · Cited by 281
Self-citationAggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics
Miczek, K. A., Weerts, E. M., Vivian, J. A., & Barros, H. M. (1995) · Psychopharmacology · doi:10.1007/bf02245590 · Cited by 275
The American Association for Research into Nervous and Mental Diseases, Davis, M., Walker, D. L., & Lee, Y. (1997) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1997.0149 · Cited by 254
Self-citation5-Hydroxytryptamine pathways in anxiety and its treatment
Handley, S. L. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00004-z · Cited by 243
Amat, J., Matus-Amat, P., Watkins, L. R., & Maier, S. F. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00960-3 · Cited by 221
Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats
Walker, D. L., & Davis, M. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00441-6 · Cited by 211
Self-citationSerotonin receptors: Clinical implications
Glennon, R. A. (1990) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80158-7 · Cited by 198
Davis, M. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90084-f · Cited by 189
Self-citationAltered fear circuits in 5-HT1A receptor KO mice
Gross, C., Santarelli, L., Brunner, D., Zhuang, X., & Hen, R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01041-6 · Cited by 181
Davis, M. E., Hitchcock, J. M., & Rosen, J. B. (1988) · The Psychology of learning and motivation/The psychology of learning and motivation · doi:10.1016/s0079-7421(08)60031-6 · Cited by 157
Self-citationStressor Controllability, Anxiety, and Serotonin
Maier, S. F., & Watkins, L. R. (1998) · Cognitive Therapy and Research · doi:10.1023/a:1018794104325 · Cited by 146
Serotonin Function and Human Anxiety Disordersa
Charney, D. S., Woods, S. W., Krystal, J. H., & Heninger, G. R. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16910.x · Cited by 123
5-HT3 receptor antagonists and anxiety; a preclinical and clinical review
Olivier, B., van Wijngaarden, I., & Soudijn, W. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00065-6 · Cited by 109
The behavioral neurobiology of self-injurious behavior in rhesus monkeys
Kraemer, G. W., & Clarke, A. S. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90092-u · Cited by 101
Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm
Kehne, J. H., Cassella, J. V., & Davis, M. (1988) · Psychopharmacology · doi:10.1007/bf00735872 · Cited by 93
“A further study (Davis et al. 1987) investigated the possible involvement of serotonergic neurons or receptors (as well as other neurochemical systems) in mediating buspirone's ability to block fear enhancement of startle.”
BackgroundSelf-citationPredictive validity of the potentiated startle response as a behavioral model for anxiolytic drugs
Hijzen, T. H., Houtzager, S. W. J., Joordens, R. J. E., Olivier, B., & Slangen, J. L. (1995) · Psychopharmacology · doi:10.1007/bf02245833 · Cited by 91
“Similar effects have been found with the 5-HTla receptor agonists buspirone, gepirone and ipsapirone, although the contribution of serotonergic and dopaminergic receptor mechanisms in the attenuation of PSR by these drugs is not as yet clear ( Davis et al. 1988; Kehne et al. 1988; Mansbach and Geyer 1988).”
BackgroundGrillon, C., Chavis, C., Covington, M. F., & Pine, D. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.141 · Cited by 88
“This is also consistent with preclinical evidence in rodents showing that the serotoninergic system is not implicated in the expression of cued fear-potentiated startle (Davis et al, 1988; Kehne et al, 1988).”
Borowski, T. B., & Kokkinidis, L. (1996) · Behavioral Neuroscience · doi:10.1037//0735-7044.110.6.1349 · Cited by 89
Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands
Mansbach, R. S., & Geyer, M. A. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90283-x · Cited by 86
Blanchard, D. C., Shepherd, J. K., Rodgers, R. J., & Blanchard, R. J. (1992) · Psychopharmacology · doi:10.1007/bf02244826 · Cited by 84
Anxiolytic-like effects of glycine receptor ligands in the rat potentiated startle test
Anthony, E. W., & Nevins, M. E. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90397-z · Cited by 86
De Vry, J., Glaser, T., Schuurman, T., Schreiber, R., & Traber, J. (1991) · New Concepts in Anxiety · doi:10.1007/978-1-349-11847-2_7 · Cited by 82
Animal Models of Anxiety and Anxiolytic Drug Action
Treit, D., Engin, E., & McEown, K. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_17 · Cited by 89
“The anxiolytic effects of 5-HT1A-type anxiolytics occur across a wide range of doses, and the magnitude of these effects nearly matches that of benzodiazepine anxiolytics (Davis et al. 1988; Kehne et al. 1988; Mansbach and Geyer 1988; Nevins and Anthony 1994).”
BackgroundCarli, M., Prontera, C., & SAMANIN, R. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb11891.x · Cited by 84
The discovery and development of buspirone: A new approach to the treatment of anxiety
New, J. S. (1990) · Medicinal Research Reviews · doi:10.1002/med.2610100302 · Cited by 76
Tizzano, J. P., Griffey, K. I., & Schoepp, D. D. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00850-x · Cited by 75
Fletcher, P. J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00215-3 · Cited by 70
Stress Enables Reinforcement-Elicited Serotonergic Consolidation of Fear Memory
Baratta, M. V., Kodandaramaiah, S. B., Monahan, P. E., Yao, J., Weber, M. D., Lin, P.-A., Gisabella, B., Petrossian, N., Amat, J., Kim, K., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.025 · Cited by 63
“Previous studies reported that lesions or pharmacologic inactivation of the DRN did not alter fear conditioning processes in unstressed animals but did block potentiation of fear produced by a prior stressor (45,46), consistent with our finding that serotonin signaling through the 5-HT2CR has a nonessential role in fe…”
BackgroundHeldt, S. A., & Ressler, K. J. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.053 · Cited by 66
“However, lesions of the raphe nuclei failed to block disrupt fear-potentiated startle or the effect of buspirone on potentiated startle (Davis et al., 1988), suggesting the modulation of DRN activity does not effect fear as measured by potentiated startle.”
BackgroundWright, I. K., Heaton, M., Upton, N., & Marsden, C. A. (1992) · Psychopharmacology · doi:10.1007/bf02245168 · Cited by 66
“Looking at other animal models of anxiety, ipsapirone has been found active in passive avoidance behaviour (Traber et al. 1984), and in the potentiated startle paradigm ( Davis et al. 1988 ) but at doses which are at least 10 fold greater than those found to be anxiolytic by Soderpalm and co-workers (1989).”
BackgroundWalker, D. L., & Davis, M. (1997) · Behavioral Neuroscience · doi:10.1037//0735-7044.111.4.692 · Cited by 61
Self-citationGABA-A and 5-HT1A Receptor Agonists Block Expression of Fear-Potentiated Startle in Mice
Risbrough, V. B., Brodkin, J. D., & Geyer, M. A. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300079 · Cited by 57
Effect of serotoninergic drugs on stress-induced hyperthermia (SIH) in mice
Lecci, A., Borsini, F., Mancinelli, A., D'Aranno, V., Stasi, M. A., Volterra, G., & Meli, A. (1990) · Journal of Neural Transmission · doi:10.1007/bf01272765 · Cited by 57
Clark, M. S., Vincow, E. S., Sexton, T. J., & Neumaier, J. F. (2004) · Brain Research · doi:10.1016/j.brainres.2004.01.070 · Cited by 60
Liang, K. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00561.x · Cited by 60
Matsuda, T., Yoshikawa, T., Suzuki, M., Asano, S., Somboonthum, P., Takuma, K., Nakano, Y., Morita, T., Nakasu, Y., Kim, H. S., et al. (1995) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.69.357 · Cited by 51
Vale, A. L., Green, S., Montgomery, A. M. J., & Shafi, S. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200306 · Cited by 51
Rodgers, R. J., & Shepherd, J. K. (1989) · Psychopharmacology · doi:10.1007/bf00445561 · Cited by 51
“1988), and a contribution of dopamine receptor antagonism to the anxiolytic efficacy of these drugs has been indirectly indicated by recent findings (e.g., Pich and Samanin 1986; Costall et al. 1987; Davis et al. 1988).”
ResultModification of the Anxiolytic Action of 5-HT1A Compounds by GABA–Benzodiazepine Agents in Rats
Fernández‐Guasti, A., & López‐Rubalcava, C. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00482-6 · Cited by 50
Winslow, J. T., Noble, P. L., & Davis, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.012 · Cited by 49
Self-citationPhasic and Sustained Fear are Pharmacologically Dissociable in Rats
Miles, L., Davis, M., & Walker, D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.29 · Cited by 47
Self-citationBenzodiazepines, putative anxiolytics and animal models of anxiety
Green, S. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90070-b · Cited by 47
Serotonergic Mechanisms in Anxiolytic Effect of Tandospirone in the Vogel Conflict Test
Shimizu, H., Tatsuno, T., Tanaka, H., Hirose, A., Araki, Y., & Nakamura, M. (1992) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.59.105 · Cited by 46
Behavioural studies on WAY100289, a novel 5-HT3 receptor antagonist, in two animal models of anxiety
Bill, D. J., Fletcher, A., Glenn, B., & Knight, M. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90186-8 · Cited by 45
Effects of buspirone in the geller‐seifter conflict test with incremental shock
Howard, J. L., & Pollard, G. T. (1990) · Drug Development Research · doi:10.1002/ddr.430190105 · Cited by 44
Fletcher, P. J., & Davies, M. (1990) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1990.tb12961.x · Cited by 44
Schmid, S., & Fendt, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.08.002 · Cited by 43
Anxiogenic treatments do not increase fear-potentiated startle in mice
Risbrough, V. B., & Geyer, M. A. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.006 · Cited by 42
Barrett, J. E. (1991) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-6419-0_3 · Cited by 39
Melia, K. R., & Davis, M. (1991) · Physiology & Behavior · doi:10.1016/0031-9384(91)90286-w · Cited by 36
Self-citationRobinson, O. J., Overstreet, C., Allen, P. S., Pine, D. S., & Grillon, C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.43 · Cited by 35
Wilkinson, L. S., Humby, T., Robbins, T. W., & Everitt, B. J. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00627.x · Cited by 34
Przegaliński, E., Chojnacka-Wójcik, E., & Filip, M. (1992) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1992.tb05521.x · Cited by 34
Effect of serotonergic drugs on negative contrast in consummatory behavior
Flaherty, C. F., Grigson, P. S., Demetrikopoulos, M. K., Weaver, M. S., Krauss, K. L., & Rowan‐Szal, G. A. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90080-2 · Cited by 32
Joordens, R. J. E., Hijzen, T. H., & Olivier, B. (1998) · Psychopharmacology · doi:10.1007/s002130050729 · Cited by 31
Evidence for the involvement of 5-HT1A receptors in the anticonflict effect of ipsapirone in rats
Chojnacka-Wójcik, E., & Przegaliński, E. (1991) · Neuropharmacology · doi:10.1016/0028-3908(91)90177-d · Cited by 31
Fear-potentiated startle response is remarkably similar in two laboratories
Joordens, R. J. E., Hijzen, T. H., Olivier, B., & Peeters, B. W. M. M. (1996) · Psychopharmacology · doi:10.1007/bf02246344 · Cited by 29
“1988; Mansbach and Geyer 1988), although the effect of two other 5-HT1A receptor agonists, 8-OH-DPAT and ipsapirone, on startle potentiation is less clear (Davis et al. 1988; Kehne et al. 1988; Mansbach and Geyer 1988).”
BackgroundInfusion of flesinoxan into the amygdala blocks the fear-potentiated startle
Groenink, L., Joordens, R. J. E., Hijzen, T. H., Dirks, A., & Olivier, B. (2000) · Neuroreport · doi:10.1097/00001756-200007140-00043 · Cited by 30
Effects of 5-HT1A receptor ligands on a safety signal withdrawal procedure of conflict in the rat
Charrier, D., Dangoumau, L., Hamon, M., Puech, A. J., & Thiébot, M.-H. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90528-2 · Cited by 29
Morrison, K. E., & Cooper, M. A. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.005 · Cited by 29
“Although early studies indicated that 5-HT1A receptors did not play an important role in fear-potentiated startle (Davis et al., 1988; Melia and Davis, 1991), later research found that administration of a 5-HT1A receptor partial agonist reduced the expression of fear-potentiated startle (Risbrough…”
Effects of 5-HT1A receptor ligands in a modified Geller-Seifter conflict model in the rat
King, C. M. F., Gommans, J., Joordens, R. J. E., Hijzen, T. H., Maes, R. A. A., & Olivier, B. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00114-3 · Cited by 26
Harris, A. C., Atkinson, D. M., Aase, D. M., & Gewirtz, J. C. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.048 · Cited by 25
“, 2004), yet does not alter startle mplitude on its own (Harris et al., 2004, see also Davis, 1979; avis et al., 1988; Swerdlow et al., 1991; Mansbach et al., 1992; ijzen et al., 1995; Fendt and Mucha, 2001).”
BackgroundThe role of postsynaptic 5-HT1A receptors in the anticonflict effect of ipsapirone
Przegaliński, E., Tatarczynska, E., Kłodzińska, A., & Chojnacka-Wójcik, E. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90150-3 · Cited by 25
The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity
Rijnders, H. J., & Slangen, J. L. (1993) · Psychopharmacology · doi:10.1007/bf02257407 · Cited by 24
“Data are not consistent, however, as Davis et al. (1988) concluded that serotonin does not mediate the anxiolytic effect of buspirone in the fear-potentiated startle paradigm.”
BackgroundThompson, B. L., & Rosen, J. B. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.024 · Cited by 23
“Buspirone has been shown to reduce fear in the elevated plus maze, the social interaction test and fear-potentiated startle (Davis et al., 1988; Dunn et al., 1989).”
BackgroundPrzegaliński, E., Tatarczynska, E., & Chojnacka-Wójcik, E. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00087-m · Cited by 21
Protracted manifestations of acute dependence after a single morphine exposure
Rothwell, P. E., Thomas, M. J., & Gewirtz, J. C. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2425-y · Cited by 21
“Previous studies from our lab and others indicate that injection with 2.5 mg/kg naloxone does not alter startle amplitude in rodents that have never been exposed to morphine (Davis et al. 1988; Glover and Davis 2008; Harris et al. 2004; Hijzen et al. 1995; Rothwell et al. 2009).”
InfluentialAnimal Models of Anxiety and the Screening and Development of Novel Anxiolytic Drugs
Sanger, D. J. (2003) · Humana Press eBooks · doi:10.1385/0-89603-177-2:147 · Cited by 19
Animal models for Clinical Psychopharmacology: Depression, Anxiety, Schizophrenia
Willner, P. (1990) · International Review of Psychiatry · doi:10.3109/09540269009026601 · Cited by 20
Effects of ipsapirone on the behaviour of mice during social encounters
Cutler, M. G. (1988) · Neuropharmacology · doi:10.1016/0028-3908(88)90065-2 · Cited by 18
Dose-dependent effects of buspirone on behavior and cerebral glucose metabolism in rats
Freo, U., Pietrini, P., Pizzolato, G., Furey-Kurkjian, M. L., Merico, A., Ruggero, S., Dam, M., & Battistin, L. (1995) · Brain Research · doi:10.1016/0006-8993(95)00140-l · Cited by 16
Groenink, L., Verdouw, P. M., Zhao, Y., ter Heegde, F., Wever, K. E., & Bijlsma, E. Y. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06307-1 · Cited by 13
“Anxiolytic drugs would be less effective in reducing fear potentiation when high noise intensities are used (Davis et al. 1988).”
BackgroundZhao, Y., Bijlsma, E. Y., ter Heegde, F., Verdouw, M. P., Garssen, J., Newman-Tancredi, A., & Groenink, L. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5124-0 · Cited by 12
McQueen, D. A., Overstreet, D. H., Ardayfio, P. A., & Commissaris, R. L. (2001) · Behavioural Pharmacology · doi:10.1097/00008877-200111000-00012 · Cited by 11
Przegaliński, E., Filip, M., Chojnacka-Wójcik, E., & Tatarczynska, E. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90290-9 · Cited by 11
Preclinical evidence for the anxiolytic activity of 5‐HT3 receptor antagonists: A review
Olivier, B., Mos, J., Heyden, J. V. D., van der Poel, G., Tulp, M. T. M., Slangen, J. L., & Jonge, R. D. (1992) · Stress Medicine · doi:10.1002/smi.2460080211 · Cited by 10
Tokuyama, S., Takahashi, M., & KANETO, H. (1993) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.61.237 · Cited by 8
Effects of anxiety drugs on the modification of the acoustic startle reflex by noise gaps
Hijzen, T. H., Rijnders, H. J., & Slangen, J. L. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90240-3 · Cited by 6
Farooq, R., Haleem, D. J., & Haleem, M. A. (2007) · PubMed · Cited by 5
Davis, M. E. (1991) · Elsevier eBooks · doi:10.1016/b978-0-08-040698-5.50013-2 · Cited by 7
Self-citationChapter 2. Antianxiety Agents and Anticonvulsants
Hrib, N. J., & Martin, L. L. (1989) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60524-2 · Cited by 4
Modelos animales de ansiedad incondicionada (I)
Cárdenas, C., & Navarro, J. (2002) · Psiquiatría Biológica · Cited by 2
Chemisch neuartige Tranquilizer und Hypnotika
Riederer, P. F., Laux, G., & Pöldinger, W. (1995) · Springer eBooks · doi:10.1007/978-3-7091-6593-5_5 · Cited by 2
Potentiation of the Startle Reflex as a Behavioral Measure of Anxiety
Gewirtz, J. C., & Radke, A. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_11 · Cited by 1
Multiple serotonergic influences on startle responding
Geyer, M. A. (1991) · Journal of Psychopharmacology · doi:10.1177/026988119100500421 · Cited by 1
Prenatal stress alters fear-conditioned behaviors and the response to serotonergic drugs
Griffin, W. C. (2001) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.1432 · Cited by 2
Smith, S. M., & Hughes, D. (1989) · Brain Research · doi:10.1016/0006-8993(89)91172-4
ASSESSMENT OF NEUROTENSIN RECEPTOR AGONIST EFFECTS ON FEAR-POTENTIATED STARTLE
Avond, V., & Aaron, M. F. (2016)
Emilien, G., Dinan, T. G., Lepola, U. M., & Durlach, C. (2002) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8157-9_9
Effects of 5-HT1A Receptors on the Development of Stress-Induced Changes in Behavior
Bader, L. R. (2013) · Cited by 1
Efeito do esteroide anabolico nandrolona sobre o nivel de ansidade em ratos
Rocha, V. D. M. (2006) · doi:10.47749/t/unicamp.2006.390475 · Cited by 1
Metadata
- Authors
- Davis, M., Cassella, J. V., & Kehne, J. H.
- Affiliations
- Yale University (US)
- ORCID
- Cassella, J. V.
- Venue
- Psychopharmacology
- Published
- 1988
- Volume
- 94
- Issue
- 1
- Pages
- 14-20
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2015340606
- Cited by
- 94
- References
- 44
- Citations by year
- 2023: 1 · 2018: 1 · 2016: 2 · 2015: 1 · 2013: 1 · 2012: 1
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 25642, MH 00004)
- National Institute of Neurological Disorders and Stroke (NS-18033)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Keywords
- buspirone, serotonin, 5-HT1A receptor, fear-potentiated startle, anxiolytic effects, dorsal raphe nucleus, median raphe nucleus, cinanserin, cyproheptadine, 8-OH-DPAT, ipsapirone, benzodiazepine receptor, naloxone, yohimbine, p-chlorophenylalanine, p-chloroamphetamine, acoustic startle response
- MeSH terms
- Acoustic Stimulation, Animals, Buspirone, Conditioning, Operant, Fear, Male, Fenclonine, Pyrimidines, Raphe Nuclei, Rats, Inbred Strains, Serotonin, Serotonin Antagonists, Reflex, Startle, Tetrahydronaphthalenes, Anti-Anxiety Agents, 8-Hydroxy-2-(di-n-propylamino)tetralin, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.